TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London
About this trial
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
Eligibility criteria
Qualifiers
Written Informed consent
Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.
Agreement to be followed up at a TRACERx EVO site
Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery
Disqualifiers
Other active malignancy
Any other* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).
Any other* current malignancy or malignancy diagnosed or relapsed within the past 3 years**.
*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 3 trial groupsSponsors and collaborators
University College, London
Lead sponsor
Cancer Research UK
Collaborator
Source ClinicalTrials.gov